PRESS RELEASE FROM FUTURE SCIENCE GROUP

September 2014
Contact: Leela Ripton
Marketing Manager, Future Science Group
Tel: +44 (0) 20 8371 6090
Email: lripton@future-science-group.com

Significant Impact Factor Uplift for Future Science Group’s Key Biotech Journals

Epigenomics Achieves 115% Increase to 5.215 Five Years After Launch

The independent British publisher, Future Science Group, today announced significant Impact Factor increases for two of its key journals: Epigenomics and Nanomedicine. The Impact Factor of Epigenomics increased 115% to 5.215, while Nanomedicine increased 11% to 5.824. Three other titles also posted increases: Future Virology (1.0, +4%), Immunotherapy, (2.44, +2%) and Future Medicinal Chemistry (4.0, +21%).

“These increases, particularly the 115% increase in Epigenomics’ Impact Factor, demonstrate our specialism in breakthrough areas of science. These increases are organic and have been driven entirely by acceptance from the scientific community,” explained Phil Garner, Managing Director. “To think that Epigenomics is only five years old and it has an Impact Factor over 5 – that’s pretty remarkable.”

The Journal of Comparative Effectiveness Research also welcomed its first Impact Factor of 1.119. Launched in 2012, the Journal of Comparative Effectiveness Research is presently the only journal with this focus that is indexed on MEDLINE.

For more information on these and other titles published by Future Science Group, visit: http://www.futuresciencegroup.com

-- ENDS --

For further information please contact:
Leela Ripton, Marketing Manager, Future Science Group
T: +44 (0) 20 8371 6090 F: +44 (0) 20 8343 2313 E: lripton@future-science-group.com

ABOUT FUTURE SCIENCE GROUP

Founded in 2001, Future Science Group is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. Future Science Group’s portfolio consists of two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business, Future Science Group
develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.
http://www.futuresciencegroup.com/